NKG2A是免疫治疗耐药且MHC-I异质性三阴性乳腺癌的治疗脆弱点
该研究探讨三阴性乳腺癌(TNBC)对免疫检查点抑制(ICI)耐药的机制,发现肿瘤内MHC-I表达异质性导致NK细胞浸润增加但功能受抑制,且与抗PD-L1治疗临床耐药相关。联合抗NKG2A和抗PD-L1治疗可在MHC-I异质性小鼠模型中恢复完全缓解,依赖活化的肿瘤浸润NK和CD8+ T细胞。
要点
- TNBC患者肿瘤内MHC-I表达存在异质性。
- MHC-I异质性肿瘤通过NKG2A抑制NK细胞功能。
- 联合抗NKG2A和抗PD-L1可恢复MHC-I异质性小鼠模型的完全缓解。
核心结论
- MHC-I异质性表达驱动抗PD-L1治疗耐药,NKG2A是克服耐药的潜在靶点。
- 联合抗NKG2A和抗PD-L1治疗可恢复MHC-I异质性小鼠模型的完全缓解,依赖活化的肿瘤浸润NK和CD8+ T细胞。
研究设计与样本
- 研究使用小鼠模型和人类乳腺肿瘤样本,采用空间技术分析MHC-I表达异质性与临床耐药的关系。
主要发现
- 在小鼠模型中,MHC-I缺失消除抗肿瘤免疫和ICI应答,而肿瘤内MHC-I异质性导致NK细胞浸润增加,呈IFNγ依赖方式。
- 空间技术分析显示,MHC-I异质性与抗PD-L1治疗临床耐药相关,且人类乳腺肿瘤中NK:T细胞比值升高。
- MHC-I异质性肿瘤需要NKG2A来抑制NK细胞功能。
- 联合抗NKG2A和抗PD-L1治疗在MHC-I异质性小鼠模型中恢复完全缓解,依赖活化的肿瘤浸润NK和CD8+ T细胞。
临床怎么用
- 作者认为,类似策略可能在临床试验中增强患者获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Despite the success of immune checkpoint inhibition (ICI) in treating cancer, patients with triple-negative breast cancer (TNBC) often develop resistance to therapy, and the underlying mechanisms are unclear. MHC-I expression is essential for antigen presentation and T-cell-directed immunotherapy responses. This study demonstrates that TNBC patients display intratumor heterogeneity in regional MHC-I expression. In murine models, loss of MHC-I negates antitumor immunity and ICI response, whereas intratumor MHC-I heterogeneity leads to increased infiltration of natural killer (NK) cells in an IFNγ-dependent manner. Using spatial technologies, MHC-I heterogeneity is associated with clinical resistance to anti-programmed death (PD) L1 therapy and increased NK:T-cell ratios in human breast tumors. MHC-I heterogeneous tumors require NKG2A to suppress NK-cell function. Combining anti-NKG2A and anti-PD-L1 therapies restores complete response in heterogeneous MHC-I murine models, dependent on the presence of activated, tumor-infiltrating NK and CD8+ T cells. These results suggest that similar strategies may enhance patient benefit in clinical trials. SIGNIFICANCE: Clinical resistance to immunotherapy is common in breast cancer, and many patients will likely require combination therapy to maximize immunotherapeutic benefit. This study demonstrates that heterogeneous MHC-I expression drives resistance to anti-PD-L1 therapy and exposes NKG2A on NK cells as a target to overcome resistance. This article is featured in Selected Articles from This Issue, p. 201.
引用
- Taylor BC, Sun X, Gonzalez-Ericsson PI, et al. NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer. Cancer Discov. 2024. PMID: 37791898. doi:10.1158/2159-8290.CD-23-0519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。